Biote Corp Net Income Over Time
| BTMD Stock | USD 2.13 0.04 1.91% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Biote Corp Performance and Biote Corp Correlation. Will Health Care Equipment & Supplies sector continue expanding? Could Biote diversify its offerings? Factors like these will boost the valuation of Biote Corp. Projected growth potential of Biote fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Biote Corp data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth (0.33) | Earnings Share 0.79 | Revenue Per Share | Quarterly Revenue Growth (0.07) | Return On Assets |
biote Corp's market price often diverges from its book value, the accounting figure shown on Biote's balance sheet. Smart investors calculate Biote Corp's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Biote Corp's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Biote Corp's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Biote Corp should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Biote Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Analysis
Compare biote Corp and related stocks such as Joint Corp, Inovio Pharmaceuticals, and Spero Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| JYNT | (736.3 K) | (736.3 K) | (736.3 K) | 155.6 K | (3 M) | (8.8 M) | (15.2 M) | (3.3 M) | 253.1 K | 3.3 M | 13.2 M | 7.6 M | 626.7 K | (9.8 M) | (5.8 M) | (6.7 M) | (6.3 M) |
| INO | (6.6 M) | (15.3 M) | (19.7 M) | (66 M) | (36.1 M) | (29.2 M) | (73.7 M) | (88.2 M) | (97 M) | (119.4 M) | (166.4 M) | (303.7 M) | (279.8 M) | (135.1 M) | (107.3 M) | (96.5 M) | (101.4 M) |
| SPRO | (10.2 M) | (10.2 M) | (10.2 M) | (10.2 M) | (10.2 M) | (10.2 M) | (25.5 M) | (46.1 M) | (41.7 M) | (60.2 M) | (77.5 M) | (89.8 M) | (46.4 M) | 22.8 M | (68.6 M) | (61.7 M) | (64.8 M) |
| ABOS | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.3 M) | (100.6 M) | (42.9 M) | (52.4 M) | (102.3 M) | (92.1 M) | (87.5 M) |
| MCRB | (3.1 M) | (3.1 M) | (3.1 M) | (6.1 M) | (16.7 M) | (54.8 M) | (91.6 M) | (89.4 M) | (98.9 M) | (70.3 M) | (89.1 M) | (65.6 M) | (250.2 M) | (113.7 M) | 136 K | 122.4 K | 128.5 K |
| SCLX | (178.6 M) | (178.6 M) | (178.6 M) | (178.6 M) | (178.6 M) | (178.6 M) | (178.6 M) | (178.6 M) | (178.6 M) | (178.6 M) | (47.5 M) | (88.4 M) | (23.4 M) | (114.3 M) | (72.8 M) | (83.7 M) | (87.9 M) |
| ACTU | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (24.7 M) | (27.3 M) | (24.6 M) | (25.8 M) |
| VOR | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (10.8 M) | (43.3 M) | (68.9 M) | (92.1 M) | (117.9 M) | (116.9 M) | (105.2 M) | (100 M) |
| ANIK | (1.6 M) | 8.5 M | 11.8 M | 20.6 M | 38.3 M | 30.8 M | 32.5 M | 31.8 M | 18.7 M | 27.2 M | (24 M) | 4.1 M | (14.9 M) | (82.7 M) | (56.4 M) | (50.7 M) | (48.2 M) |
| LUCD | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (4.4 M) | (8.3 M) | (28.1 M) | (56.2 M) | (52.7 M) | (45.5 M) | (41 M) | (43 M) |
biote Corp and related stocks such as Joint Corp, Inovio Pharmaceuticals, and Spero Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in biote Corp financial statement analysis. It represents the amount of money remaining after all of biote Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| biote Corp | BTMD |
Specialization | Health Care, Health Care Equipment & Services |
| Business Address | 1875 W Walnut |
| Exchange | NASDAQ Exchange |
USD 2.13
Check out Biote Corp Performance and Biote Corp Correlation. For information on how to trade Biote Stock refer to our How to Trade Biote Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Biote Corp technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.